Lung Cancer News and Research RSS Feed - Lung Cancer News and Research Twitter

Lung cancer is the world's most common cancer and kills more people than any other cancer. In 2008, approximately 1.52 million new cases of lung cancer were diagnosed worldwide, with 1.31 million people dying from the disease.(14) In the United States, an estimated 161,840 deaths, accounting for 29 percent of all cancer deaths, occurred in 2008, according to the American Cancer Society (ACS).
NCCN ORP awards four research grants to advance development of nintedanib

NCCN ORP awards four research grants to advance development of nintedanib

The National Comprehensive Cancer Network Oncology Research Program has awarded four grants to investigators to evaluate and define the clinical effectiveness of the investigational compound nintedanib (BIBF 1120) in non-small cell lung, colorectal, and gastrointestinal cancers. [More]
Chemotherapy may benefit advanced pulmonary carcinoid tumour patients

Chemotherapy may benefit advanced pulmonary carcinoid tumour patients

A review of patients with advanced pulmonary carcinoid tumours shows that they can be responsive to chemotherapy. [More]
Antacids linked to reduced erlotinib efficacy

Antacids linked to reduced erlotinib efficacy

Acid suppression therapy may negatively impact outcome among patients receiving erlotinib for advanced non-small-cell lung cancer, Canadian study findings show. [More]
Seno Medical completes enrollment in PIONEER Pivotal Study of Imagio for diagnosing breast cancer

Seno Medical completes enrollment in PIONEER Pivotal Study of Imagio for diagnosing breast cancer

Seno Medical Instruments, Inc., the company pioneering the development of opto-acoustic technology as a new tool to improve the process of diagnosing breast cancer, announced today it has completed active enrollment of subjects in its U.S.-based PIONEER Pivotal Study of Imagio. [More]
FDG-PET technology less accurate in diagnosing lung cancer in regions where infections are common

FDG-PET technology less accurate in diagnosing lung cancer in regions where infections are common

A new analysis of published studies found that FDG-PET technology is less accurate in diagnosing lung cancer versus benign disease in regions where infections like histoplasmosis or tuberculosis are common. Misdiagnosis of lung lesions suspicious for cancer could lead to unnecessary tests and surgeries for patients, with additional potential complications and mortality. [More]
Alectinib promise for crizotinib-resistant NSCLC

Alectinib promise for crizotinib-resistant NSCLC

Alectinib has shown promising antitumour activity in patients with ALK-rearranged non-small-cell lung cancer that is resistant to crizotinib, researchers report. [More]
Circulating tumour cell clinical research collaboration announced between EKF Diagnostics and Massachusetts General Hospital

Circulating tumour cell clinical research collaboration announced between EKF Diagnostics and Massachusetts General Hospital

EKF Diagnostics, the global diagnostics company, announces that it has entered into a two year research collaboration with Massachusetts General Hospital (MGH), a global leader in successfully bridging innovative science with state-of-the-art clinical medicine, to develop PointMan™ assays that can effectively detect treatable cancer mutations in blood samples. [More]
Viewpoints: CHIP funding needed; GOP's flawed plan to make 'the pill' OTC; millennials' health issues

Viewpoints: CHIP funding needed; GOP's flawed plan to make 'the pill' OTC; millennials' health issues

Federal financing for a beneficial health insurance program for low-income children, known as the Children's Health Insurance Program or CHIP, will run out next year unless Congress agrees to extend it. Bills are pending in both the House and the Senate to extend financing for four years, to 2019. Congress should approve the extension in the lame-duck session after the midterm elections so that families and state officials will know what the future holds. The program needs to be maintained amid uncertainty as to whether other good coverage will be available for these children (9/21). [More]
Olympus signs agreement with Brainlab to become exclusive U.S. distributor of Kick Navigation

Olympus signs agreement with Brainlab to become exclusive U.S. distributor of Kick Navigation

Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, among other core businesses, announced today it has reached a deal with Munich-based Brainlab to be the exclusive U.S. distributor of Kick Navigation. [More]
Disrupting cancer regulator MYC: an interview with Professor Kim Janda

Disrupting cancer regulator MYC: an interview with Professor Kim Janda

MYC is an oncogenic member of the basic helix-loop-helix-leucine zipper transcription factor family. In its monomeric form, MYC’s tertiary structure is intrinsically disordered and the protein is transcriptionally inactive. [More]
Ramucirumab effective second-line option for NSCLC

Ramucirumab effective second-line option for NSCLC

The monoclonal antibody ramucirumab, when added to second-line docetaxel, significantly improves the overall survival of patients with stage IV non-small-cell lung cancer, show the findings of the REVEL trial. [More]
Survival benefits with erlotinib plus bevacizumab in EGFR-Mutated NSCLC

Survival benefits with erlotinib plus bevacizumab in EGFR-Mutated NSCLC

Combining erlotinib with bevacizumab could prolong progression-free survival in patients being treated for epidermal growth factor receptor-mutated non-small-cell lung cancer, phase II trial results suggest. [More]
S-1 plus radiotherapy shows promise in elderly NSCLC patients

S-1 plus radiotherapy shows promise in elderly NSCLC patients

Concurrent administration of S-1 chemotherapy and radiotherapy has a favourable impact on survival in elderly patients with locally advanced non-small-cell lung cancer, a phase II trial has found. [More]
Lobectomy and segmentectomy have similar efficacy in stage I NSCLC

Lobectomy and segmentectomy have similar efficacy in stage I NSCLC

Lobectomy and anatomic segmentectomy appear to offer similar perioperative and oncological outcomes in patients with stage I non-small-cell lung cancer, analysis suggests. [More]
Current smokers at increased risk of developing SPLC

Current smokers at increased risk of developing SPLC

Non-small cell lung cancer (NSCLC) survivors who never smoked or who are former smokers at the time of diagnosis have a lower risk of developing secondary primary lung cancers (SPLC) compared to those who are current smokers, suggesting that increased tobacco exposure is associated with a higher risk of SPLC, according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting. [More]

EnGeneIC receives award from Cancer Institute NSW for groundbreaking cancer research

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, announced that, together with the Asbestos Disease Research Institute, it has received the 2014 Cancer Institute New South Wales Premier’s Award for Excellence in Translational Cancer Research. [More]
Thoracic radiotherapy reduces cancer recurrence in SCLC patients, shows new study

Thoracic radiotherapy reduces cancer recurrence in SCLC patients, shows new study

Treating advanced small-cell lung cancer (SCLC) with thoracic (or chest) radiation therapy in addition to standard treatment significantly prolongs long-term survival and reduces cancer recurrence in the chest by almost 50%, according to new research published in The Lancet and being presented simultaneously at ASTRO's 2014 Annual Meeting in San Francisco. [More]
Research roundup: Prevention services for seniors; drug shortages

Research roundup: Prevention services for seniors; drug shortages

This policy brief reports the findings of a systematic review conducted by the Community Health Innovations in Prevention for Seniors (CHIPS) project. ... Clinical preventive services such as colorectal cancer screening and pneumococcal immunization can help reduce rates of premature death and disability. Yet, many older adults are not receiving the full set of clinical preventive services that have been proven effective and are considered "high value" in terms of their costs per life saved. Rates are particularly low among racial and ethnic minority older adults compared to national goals. [More]
Lung cancer screening could save thousands, study suggests

Lung cancer screening could save thousands, study suggests

Experts from the Centers of Medicare and Medicaid Services (CMS) have weighed up the pros and cons of lung cancer screening to determine whether Medicare-eligible individuals would actually benefit from annual testing. [More]
Cancer Research UK, CRT partner with Asterias to trail novel immunotherapy treatment for lung cancer

Cancer Research UK, CRT partner with Asterias to trail novel immunotherapy treatment for lung cancer

CANCER RESEARCH UK and Cancer Research Technology , the charity's development and commercialisation arm, have reached an agreement with Asterias Biotherapeutics, Inc., a biotechnology company in the emerging field of regenerative medicine, to take forward Asterias' novel immunotherapy treatment AST-VAC2 into clinical trials in subjects with non-small cell lung cancer. [More]